BR112022026208A2 - Anticorpos de ccr8 para aplicações terapêuticas - Google Patents

Anticorpos de ccr8 para aplicações terapêuticas

Info

Publication number
BR112022026208A2
BR112022026208A2 BR112022026208A BR112022026208A BR112022026208A2 BR 112022026208 A2 BR112022026208 A2 BR 112022026208A2 BR 112022026208 A BR112022026208 A BR 112022026208A BR 112022026208 A BR112022026208 A BR 112022026208A BR 112022026208 A2 BR112022026208 A2 BR 112022026208A2
Authority
BR
Brazil
Prior art keywords
antibodies
methods
ccr8
tools
conjugates
Prior art date
Application number
BR112022026208A
Other languages
English (en)
Inventor
Filarsky Katharina
Von Ahsen Oliver
Berndt Sandra
Maria Nadler Wiebke
Ellinger Philipp
Stelte-Ludwig Beatrix
Hoff Sabine
Roider Helge
Weber Ernst
Trautwein Mark
Votsmeier Christian
Pawlowski Nikolaus
Gritzan Uwe
Buchmann Pascale
Bertling Christian
Paz Pedro
Tseng Su-Yi
Jones Patrick
Lyn Oh Phaik
GORJANACZ Matyas
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR112022026208A2 publication Critical patent/BR112022026208A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTICORPOS DE CCR8 PARA APLICAÇÕES TERAPÊUTICAS. A presente invenção refere-se a ferramentas e métodos para gerar anticorpos que se ligam especificamente a receptores de quimiocinas, tais como receptores de quimiocinas CC ou CXC. São fornecidos polipeptídeos sulfatados isolados e seus conjugados, que podem ser usados, por exemplo, como antígenos ou para panning fora do alvo para facilitar a geração de anticorpos receptores de quimiocina anti-humano, anticinomolgo e/ou anticamundongo, por exemplo para a geração de anticorpos com CDRs totalmente humanas e/ou outras propriedades favoráveis para uso terapêutico. Além disso, a invenção refere-se a anticorpos e seus conjugados que podem ser obtidos pela aplicação de tais ferramentas e métodos. São fornecidos anticorpos que se ligam especificamente ao CCR8 humano, cinomolgo e/ou murino com propriedades favoráveis para uso terapêutico, tais como anticorpos de reação cruzada, anticorpos totalmente humanos, anticorpos de baixa internalização (incluindo não internalizantes) e anticorpos que induzem eficazmente ADCC e/ou ADCP em células Treg. Também são fornecidos usos médicos dos anticorpos ou conjugados inventivos e/ou métodos de tratamento compreendendo a administração dos anticorpos a um paciente ou indivíduo, sozinho ou em combinação. Biomarcadores, métodos de estratificação e métodos de diagnóstico são também fornecidos para prever ou avaliar a capacidade de resposta à monoterapia ou terapia combinada de anticorpos anti-CCR8. Além disso, ferramentas e métodos para produzir os referidos anticorpos, composições farmacêuticas, usos diagnósticos dos anticorpos e kits com instruções de uso são fornecidos.
BR112022026208A 2020-06-26 2021-06-25 Anticorpos de ccr8 para aplicações terapêuticas BR112022026208A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062705434P 2020-06-26 2020-06-26
US202062705608P 2020-07-07 2020-07-07
EP20205426 2020-11-03
PCT/EP2021/067504 WO2021152186A2 (en) 2020-06-26 2021-06-25 Ccr8 antibodies for therapeutic applications

Publications (1)

Publication Number Publication Date
BR112022026208A2 true BR112022026208A2 (pt) 2023-01-17

Family

ID=76553783

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022026121A BR112022026121A2 (pt) 2020-06-26 2021-06-25 Terapia de anticorpo anti-ccr8: biomarcadores e terapias de combinação
BR112022026208A BR112022026208A2 (pt) 2020-06-26 2021-06-25 Anticorpos de ccr8 para aplicações terapêuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022026121A BR112022026121A2 (pt) 2020-06-26 2021-06-25 Terapia de anticorpo anti-ccr8: biomarcadores e terapias de combinação

Country Status (14)

Country Link
US (3) US20230250178A1 (pt)
EP (5) EP4172201A2 (pt)
JP (5) JP2023531991A (pt)
KR (2) KR20230028780A (pt)
CN (6) CN117653725A (pt)
AU (2) AU2021295721A1 (pt)
BR (2) BR112022026121A2 (pt)
CA (3) CA3188142A1 (pt)
CL (1) CL2022003747A1 (pt)
IL (2) IL298896A (pt)
MX (2) MX2022015968A (pt)
PE (1) PE20231200A1 (pt)
TW (1) TW202216771A (pt)
WO (5) WO2021260209A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
CN116589583A (zh) 2020-10-16 2023-08-15 礼新医药科技(上海)有限公司 抗ccr8单克隆抗体及其用途
WO2022211046A1 (ja) 2021-03-31 2022-10-06 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識するキメラ抗原受容体
CR20230581A (es) * 2021-06-04 2024-02-13 Amgen Inc Anticuerpos anti-CCR8 y usos de los mismos
WO2023010054A1 (en) 2021-07-27 2023-02-02 Abbvie Inc. Anti-ccr8 antibodies
CA3225986A1 (en) * 2021-08-20 2023-02-23 Hifibio (Hk) Limited Anti-ccr8 antibodies and uses thereof
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023098888A1 (en) * 2021-12-02 2023-06-08 Zai Lab (Shanghai) Co., Ltd Ccr8 antigen binding unit and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2023230473A1 (en) 2022-05-24 2023-11-30 Bristol-Myers Squibb Company Antibodies that bind to human ccr8
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
WO2023245074A2 (en) * 2022-06-14 2023-12-21 Purdue Research Foundation Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024026400A2 (en) * 2022-07-27 2024-02-01 Varian Medical Systems, Inc. Therapeutic combinations of titr effectors with radiation therapy
WO2024052517A2 (en) * 2022-09-09 2024-03-14 Bayer Aktiengesellschaft Medical use of ccr8 antibodies and dosing schedule
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024059909A1 (en) * 2022-09-21 2024-03-28 Monash University Anti-ccr8 antibodies
WO2024077239A1 (en) * 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024088346A1 (en) * 2022-10-28 2024-05-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ccr8 antibodies and uses thereof
WO2024097741A1 (en) * 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
CN117285627A (zh) * 2023-09-06 2023-12-26 百济神州(上海)生物科技有限公司 抗ccr8抗体及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6329510B1 (en) 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
AU2001250412A1 (en) 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
AU2003229753A1 (en) * 2002-05-13 2003-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
DK2921500T3 (da) 2004-07-10 2023-09-18 The Institute For Cancer Res Genetisk modificerede, humane, naturlige dræbercellelinjer
WO2007044756A2 (en) 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
CN101720368A (zh) 2007-03-09 2010-06-02 中国抗体制药有限公司 储备多样性最大化的功能性人化抗体文库之构建及应用
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
CN102648280B (zh) 2009-09-22 2014-10-08 普罗拜奥根股份公司 生产含有特定聚糖结构之分子的方法
JP2017520862A (ja) * 2014-03-27 2017-07-27 マサチューセッツ インスティテュート オブ テクノロジー 水溶性膜タンパク質ならびにその調製および使用方法
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CA2950577A1 (en) * 2014-05-27 2015-12-03 Academia Sinica Fucosidase from bacteroides and methods using the same
MA41176A (fr) 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
DK3334457T3 (da) * 2015-08-10 2020-09-21 Pepmab B V Humaniserede anti-CCR7-receptorantistoffer
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
JP7358047B2 (ja) 2016-05-16 2023-10-10 チェックマブ エス．アール．エル． 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー
EP3471752B1 (en) * 2016-06-17 2022-03-09 Varian Medical Systems, Inc. Immune modulators in combination with radiation treatment
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
ES2863412T3 (es) 2017-03-29 2021-10-11 Shionogi & Co Composición farmacéutica para el tratamiento del cáncer
CN112040951A (zh) 2018-01-31 2020-12-04 拜耳股份公司 具有nampt抑制剂的抗体药物缀合物(adc)
WO2019157098A1 (en) 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use
AU2019289506A1 (en) 2018-06-18 2021-02-04 Bayer Aktiengesellschaft Binder-drug conjugates directed against CXCR5, having enzymatically cleavable linkers and improved activity profile
CN110835374A (zh) * 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8×ctla-4双特异性抗体及其应用
EP3880215A4 (en) 2018-11-13 2023-02-15 Memorial Sloan Kettering Cancer Center COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER
EP3903817A4 (en) * 2018-12-27 2022-08-17 Shionogi & Co., Ltd. NEW ANTI-CCR8 ANTIBODY
IL294330A (en) * 2020-01-06 2022-08-01 Vaccinex Inc Anti-ccr8 antibodies and their uses
AU2021219668A1 (en) * 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
JP2023516388A (ja) 2020-03-05 2023-04-19 メモリアル スローン ケタリング キャンサー センター 抗ｃｃｒ８剤
JP2023519254A (ja) 2020-03-23 2023-05-10 ブリストル－マイヤーズ スクイブ カンパニー がんを処置するための抗ｃｃｒ８抗体
JPWO2022004760A1 (pt) 2020-06-30 2022-01-06
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP2023540661A (ja) 2020-07-03 2023-09-26 ナンキン イムノファージ バイオテック カンパニー リミテッド ＣＣＲ８阻害剤を使用してＴｒｅｇｓを標的とする方法および組成物
US20230320332A1 (en) 2020-09-11 2023-10-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric ccr8

Also Published As

Publication number Publication date
AU2021295721A1 (en) 2023-01-19
EP4171602A2 (en) 2023-05-03
CA3188142A1 (en) 2021-12-30
EP4171601A2 (en) 2023-05-03
MX2022015954A (es) 2023-01-24
TW202216771A (zh) 2022-05-01
WO2021260206A2 (en) 2021-12-30
CN116096750A (zh) 2023-05-09
EP4172204A2 (en) 2023-05-03
KR20230028453A (ko) 2023-02-28
WO2021260210A2 (en) 2021-12-30
PE20231200A1 (es) 2023-08-17
IL298910A (en) 2023-02-01
JP2023531991A (ja) 2023-07-26
US20220363768A1 (en) 2022-11-17
IL298896A (en) 2023-02-01
US11427640B1 (en) 2022-08-30
BR112022026121A2 (pt) 2023-01-17
WO2021152186A3 (en) 2021-12-02
WO2021260209A3 (en) 2022-03-10
WO2021260208A3 (en) 2022-03-17
CA3188146A1 (en) 2021-12-30
CN116234825A (zh) 2023-06-06
EP4172202A2 (en) 2023-05-03
CN116096749A (zh) 2023-05-09
WO2021152186A2 (en) 2021-08-05
JP2023531990A (ja) 2023-07-26
AU2021212327A1 (en) 2023-01-05
CN116096748A (zh) 2023-05-09
CL2022003747A1 (es) 2023-05-19
JP2023531705A (ja) 2023-07-25
CN117653725A (zh) 2024-03-08
WO2021260209A2 (en) 2021-12-30
EP4172201A2 (en) 2023-05-03
KR20230028780A (ko) 2023-03-02
MX2022015968A (es) 2023-01-24
WO2021260206A3 (en) 2022-03-17
US20230250178A1 (en) 2023-08-10
CN116096395A (zh) 2023-05-09
JP2023531988A (ja) 2023-07-26
WO2021260208A2 (en) 2021-12-30
WO2021260210A3 (en) 2022-04-14
CA3188138A1 (en) 2021-08-05
JP2023531989A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
BR112022026208A2 (pt) Anticorpos de ccr8 para aplicações terapêuticas
US20220135675A1 (en) Anti-tim-3 antibodies and use thereof
CL2012001387A1 (es) Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07)
BR112017019785A2 (pt) anticorpos terapêuticos e seus usos
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112022005423A2 (pt) Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap)
EA029791B1 (ru) Фармацевтическая композиция и способ ингибирования продукции или усиления элиминации белка p24 вич
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
ES2891336T3 (es) Combinaciones y usos de las mismas
ES2061769T3 (es) Anticuerpo monoclonal y su utilizacion.
Willingham et al. Characterization and Phase 1 trial of a B cell activating anti-CD73 antibody for the immunotherapy of COVID-19
Takheaw et al. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
AR122763A1 (es) Anticuerpos ccr8 para aplicaciones terapéuticas
WO2019244082A3 (en) Antibody drug conjugates for ablating hematopoietic stem cells
BR112022009482A2 (pt) Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo
Chauchet et al. 265 CD47xPD-L1 bispecific antibodies for cancer therapy
Grasso et al. NAV‐003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors
WO2023227644A3 (en) Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers
Hazboun Cancer Immunotherapy with CAR-T Cells for Hematological Malignancies
Triozzi et al. Clinical and immunologic effects of monoclonal antibody CC49 and interleukin-2 in patients with metastatic colorectal cancer
WO2023169985A3 (en) Combination of a fcyrllb- and a tumor antibody for use in the treatment of an fcyriib-negative cancer
WO2021195557A3 (en) Monoclonal antibodies targeting hsp70 and therapeutic uses thereof
PE20231678A1 (es) Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico